BGM Group (BGM) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed BGM Group (BGM) over the past year, losing 24.0% versus a loss of 96.3%. Over five years, BGM leads with a -98.2% price change compared with -99.9% for HURA. BGM Group is the larger company by market cap ($143.6 million vs $124.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | HURA |
|---|---|---|
| Share price | $10.75 | $1.96 |
| Market cap | $143.56M | $124.90M |
| 1-day change | +10.94% | +1.55% |
| YTD return | -90.29% | +158.92% |
| 1-year return | -96.31% | -24.03% |
| 5-year return | -98.19% | -99.87% |
| EPS (TTM) | $-4.80 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $3.43 |
| 52-week low | $6.45 | $0.41 |
| Distance from 52-week high | -96.45% | -42.86% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +310.20% |
| Average volume | 6.11K | 244.46K |
| Shares outstanding | 12.69M | 63.73M |
| Employees | — | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed BGM by 72.3 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
BGM vs HURA FAQ
Which is bigger, BGM Group or TuHURA Biosciences?
BGM Group (BGM) is larger, with a market capitalization of $143.56M compared with $124.90M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, BGM or HURA?
HURA returned -24.03% over the past 12 months, compared with -96.31% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.